Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyArticle Info
Publication History
Publication stage
In Press Journal Pre-ProofFootnotes
Funding: This research was funded by the Canadian Cardiovascular Society (CCS). The McMaster Evidence Review and Synthesis Team (MERST) was independently responsible for the data extraction, analysis, interpretation, and reporting. Dr. Diana Sherifali holds the Heather M. Arthur Population Health Research Institute/Hamilton Health Sciences Chair in Interprofessional Health Research which supported her role in this work.
Disclosures: Members of the CCS guideline committee developed the research questions and their involvement helped inform the protocol of the review and editing of the manuscript. All screening of articles, data extraction, analysis, and interpretation was conducted by MERST members, independent from the guideline Committee or funders. All authors contributed to the writing or editing of the manuscript.
Identification
Copyright
ScienceDirect
Access this article on ScienceDirectLinked Article
- Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and StrokeCanadian Journal of Cardiology
- PreviewAli et al.1 conducted a wonderful and comprehensive meta-analysis1 based on all the available cardiovascular outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is; 11 CVOTs) and glucagon-like peptide 1 receptor agonists (GLP1RAs; 8 CVOTs), drawing their main conclusion that both SGLT2is and GLP1RAs yielded the statistically significant benefits across most cardiorenal end points in the populations studied. This conclusion only emphasises the similarity between GLP1RAs and SGLT2is in cardiorenal benefits, but ignores the differences between them in specific cardiorenal outcomes.
- Full-Text
- Preview
